On-demand intermittent beclomethasone is effective for mild asthma in Brazil

Paulo Camargos1*, Alessandra Affonso2, Geralda Calazans2, Lidiana Ramalho2, Marisa L. Ribeiro2, Nulma Jentzsch2, Simone Senna2 and Renato T. Stein3

Abstract

Background: Daily inhaled corticosteroids are widely recommended for mild persistent asthma. This study aimed to assess the efficacy of the intermittent use of beclomethasone as an alternative treatment for mild persistent asthma.

Methods: In this 16-week trial, children aged 6–18 years were evaluated. Subjects in the continuous treatment arm of the study received 500 μg/day of beclomethasone, whereas the intermittent ones were given 1000 μg/day (250 μg every 6 h) in combination with albuterol for 7 days upon exacerbations or worsening of symptoms. Primary outcome (i.e., treatment failure) was the occurrence of any asthma exacerbation requiring prednisone, and co-secondary outcomes were the mean/median differences for both, (1) the pre-bronchodilator FEV1 (% predicted) and (2) asthma control test (ACT/cACT) scores, from randomization to the last follow-up visit, and beclomethasone and albuterol consumption.

Results: Ninety-four subjects from each treatment arm were included. They were comparable regarding all baseline characteristics; prednisone was used by 10 (10.6%) and 7 (7.4%) patients, respectively (95% CI −6.1 to 12.6%, for the difference; p = 0.47). Statistical analysis showed no statistically significant differences with respect to both FEV1 (p = 0.39) and ACT/cACT scores (p = 0.38). As assessed through canister weighting, children used from 0.5 to 0.7 and from 1.6 to 1.8 puffs per day of beclomethasone in the intermittent and continuous regimens, respectively. Regarding albuterol, received 0.3–0.4 (intermittent) and 0.1–0.2 (continuous) inhalations per day. There were no relevant clinical or functional differences between the two treatment regimens.

Conclusion: Clinicians might consider intermittent inhaled steroid therapy as a therapeutic regimen for mild persistent asthma.

Trial registration The Portuguese and English versions of the study protocol were submitted, approved, and registered in the Brazilian Network Platform for Clinical Trials (http://www.ensaiosclinicos.gov.br) under the primary identifier number “RBR-3gbyhk”. This platform is part of the Primary Registries in the World Health Organization Registry Network, where the trial is registered under the following Universal Trial Number: 1111-1149-4774

Keywords: Pediatric asthma, Asthma treatment, Asthma management

*Correspondence: pcamargs@medicina.ufmg.br
1 Pediatric Pulmonology Unit, University Hospital, Federal University of Minas Gerais, Avenida Alfredo Balena 190, Room 267, Belo Horizonte 30130-100, Brazil
Full list of author information is available at the end of the article

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
International guidelines consistently recommend daily use of inhaled corticosteroids (ICS) for mild persistent asthma, which accounts for the majority of persistent cases. However, three publications have evaluated the clinical benefits of an intermittent/as-needed strategy for the treatment of children with mild asthma, suggesting that although continuous treatment is associated with better disease control, the results for intermittent use were also clinically and functionally acceptable [1–3]. Studies have indicated that an on demand, intermittent regimen, combining inhaled [1, 2] or nebulized [3] corticosteroids with short acting beta 2-agonists is able to reduce the use of inhaled corticosteroids by almost 80% in these patients. In low and middle-income countries, where ICS is not widely available or affordable, reduced medication use can bring benefits for public health policies.

The present study aimed to study the efficacy of an intermittent regimen of beclomethasone dipropionate on exacerbations rate, as well as other clinical and lung function outcomes. Our hypothesis was that there would be a slight superiority in favor of the continuous regimen.

Methods
Study design
Two-arm, 16-week long, parallel, randomized open-label (i.e., with no placebo control) study, involving three centers. Participants were initially admitted to a 4-week run-in period, when they were prescribed two puffs (250 μg each) daily—even if they were given a lower dose of beclomethasone or equivalent previous to the run-in period—of HFA non-extrafine beclomethasone dipropionate (Clenil®, Chiesi, Brazil; hereafter beclomethasone), and albuterol as needed, every 4 h. Out of the two available options in Brazil, we decided to adopt the 250 μg formulation of beclomethasone instead of the 50 μg, in an attempt to reduce the number of daily puffs and achieve higher adherence rates.

In order to be included in the 16-week follow-up, patients with asthma had to be well controlled and without exacerbations during the run-in period, after which eligible patients were randomly allocated into two groups, i.e., intermittent or continuous treatment. From randomization until the end of the follow-up, patients were assessed clinically, with a complete physical examination and either the Asthma Control Test (ACT) [4] or the Childhood Asthma Control Test (cACT) [5] and pulmonary function tests. Due to the potential safety benefits regarding ICS’ side effects in the case of reduction of total daily doses, height was also systematically evaluated at every follow-up visit.

Sampling site and randomization process
Children were recruited from the city’s public health system facilities network, where they were initially evaluated by general pediatricians and then referred to and followed by a pediatric pulmonologist along with a multidisciplinary team allocated in three different secondary referral centers. Block randomization (30 patients per block) was used to assign participants into the two treatment regimens through a computer-generated random sequence of numbers.

Dosage and duration of the intervention
During the 16 weeks of the follow-up, subjects assigned to the continuous group were given 500 μg daily (250 μg bid) of beclomethasone, whereas those in the intermittent group received 1000 μg daily (1 puff of 250 μg every 6 h) of beclomethasone plus 4 puffs of albuterol every 4 h for 7 days, upon the worsening of asthma symptoms and/or the onset of any asthma exacerbation.

All inhaled medications were used through a pear-shaped, plastic, large volume (650 ml) valved spacer (Flumax®, Inside, Brazil). Subjects were instructed to assure proper use of the spacer and inhaler devices.

Inclusion criteria for admission into the run-in period
To ensure that only mild asthmatic patients would be recruited, we admitted participants that: had asthma symptoms but were naïve to controller treatment in the previous 2 years; had no asthma exacerbation in the previous 3 months; made regular use of inhaled corticosteroids in the previous 8 weeks (up to 500 μg daily of beclomethasone or equivalent); and their asthma was under control in the previous 8 weeks using 250–500 μg of beclomethasone (or equivalent) daily. Finally, in order to be included, children should have been able to perform spirometry and not have had smoked within the previous year.

Exclusion criteria
In order to preclude the recruitment of patients with other severity levels, we excluded patients that had had treatment with oral steroids in the 2 weeks prior to the run-in period or within 2 weeks of screening visits; forced expiratory volume in 1 s (FEV₁) less than 60% of predicted values [6] at the end of the run-in period; hospitalization for asthma in the previous year; presence of chronic or active disease other than asthma; asthma exacerbation in the previous 3 months or more than two in the last year; history of an exacerbation that required intensive care unit hospitalization; use of oral or injectable desensitizing immunotherapy for 3 months or more; inability to perform spirometry; and a nurse/physician
impression that the family would not adhere to prescribed treatment.

Randomization process at the end of the run-in period
Participants were selected for randomization if after the run-in period their asthma symptoms (as assessed by ACT/cACT) were controlled and FEV$_1$ was equal or greater than 75% of predicted values [6].

Definition and management of exacerbations
Exacerbations were defined as (1) the use of more than 12 puffs of albuterol daily, (2) an acute attack that led to difficulty sleeping/nighttime asthma symptoms or doing daily activities for 2 or more consecutive days, and/or (3) an unscheduled visit to one of the three secondary referral center because of worsening of asthma symptoms.

To ensure a standardized approach in both arms of the study, a written action plan form was given to patients and their parents to collect and record relevant data during the study, with particular emphasis on how to: (1) recognize asthma worsening (including difficulty sleeping/nighttime symptoms or doing daily activities for 2 or more consecutive days) and (2) manage exacerbations at home including recording the number of administered doses of albuterol and beclomethasone.

The initial home management of exacerbations should be started with the use of albuterol (3 cycles of 4–6 inhalations every 20 min and then 4 puffs every 4 h); if no improvement had been observed within the next 2–4 h, then they were instructed to add beclomethasone provisionally (1 puff of 250 μg every 6 h, i.e., 1000 μg daily). If clinical improvement or control were not achieved within 2–4 h, patients were also instructed to seek assistance by the research team at the nearest study site. The final decision to prescribe beclomethasone for up to 7 days and prednisone (1–2 mg/kg/day for 5 days) was based solely on the assessment of the pediatric pulmonologist. He also was the solely responsible for withdrawing beclomethasone among patients that needed prednisone.

Primary and co-secondary endpoints
The primary endpoint was treatment failure, pre-defined as the occurrence of any asthma exacerbation requiring oral corticosteroid, in the two groups.

Co-secondary endpoints were also pre-defined as the mean/median difference for the pre-bronchodilator FEV$_1$ (% predicted) and for ACT/cACT scoring (20 or more points means asthma control) from randomization to the last follow-up visit, and beclomethasone and albuterol consumption (expressed as number of puffs per day). Adherence rate to inhaled medicines (firstly calculated in micrograms per day and then converted to number of puffs per day) was assessed by systematic canister weighting (each actuation = 55.46 and 72.23 mg for beclomethasone and albuterol, respectively) through an analytical scale at every follow-up visit. A previous study from our group carried out in the same setting showed that the adherence assessment to beclomethasone through this method was comparable to electronic monitoring [7].

Spirometry
Forced expiratory spirometry with recording of FEV$_1$ values, was performed by an experienced technician who was blind to the treatment regimen, according to the American Thoracic Society recommendations [8]. To allow comparisons with the two previously published studies on the efficacy of on demand ICS treatment, FEV$_1$ values were expressed as a percentage of the predicted value according the equations reported by Polgar and Promadhat [6].

Height assessment
During the follow-up period, height was assessed every 2 months through a Harpenden stadiometer (ranging from 60.0 to 210.0 cm, length of 2 m, wall mounted, with a precision of 0.1 cm). Height was measured with the patient standing up, barefoot, positioned in such a way that the head, shoulders, buttocks and calves lightly touched the wall.

Allergic rhinitis assessment and treatment
Patients with allergic rhinitis (AR) enrolled in both groups were assessed through the score reported by Wilson et al. [9] and treated with continuous intranasal budesonide (32 μg/dose, bid). Each of the typical signs and symptoms of AR received a number of points, ranging from 0 (best) to 3 (worst). The total score could range from 0 to 18 points.

Statistics
Sample size
Assuming that the two regimens are in fact different, sample size calculation took into account the following parameters: (1) alpha and beta error equal to 0.05 and 0.20, respectively; (2) proportion of subjects with treatment failure of 5% (continuous arm) and 15% (intermittent arm), and a ratio of 1:1 between the two groups. A total of 282 participants were required, 141 in each group [10].

Analysis
Descriptive statistics was used to compare demographic, clinical and functional characteristics between the two groups. For longitudinal analysis of FEV$_1$, comparisons between the two groups were done by generalized
estimating equations regression model for binary response, i.e., intermittent versus continuous treatment [11]. In that case, curve fitting was plotted to demonstrate its variations during the follow-up.

Because of the specificity of its longitudinal data characteristics, comparisons of the ACT/cACT between the two groups consisted of developing linear regression with random effects model for longitudinal data, to explain the variation throughout the follow-up of each of their items [12].

The underlying assumption for these models is that the outcome is a linear function of the regression coefficients obtained for the explanatory variables.

**Results**

Figure 1 displays the study design and Fig. 2 the flow of the participants throughout the trial. As shown, 279 children were initially assessed for eligibility. Due to operational and funding constraints, only 188 were enrolled into the trial, and out of those, 94 were assigned to each of the two treatment regimens.

The baseline characteristics of the studied subjects are displayed on Table 1.

The two groups were similar regarding demographic, socioeconomic, clinical, and functional characteristics. Exacerbations were assessed at the end of follow-up and occurred in the 2nd and 3rd months of the follow-up when prednisone use was required in 10 (10.6%) and 7 (7.4%) patients of the intermittent and continuous regimens, respectively (p = 0.47). The 95% confidence interval for the difference (i.e., 3.2%) between the two (10.6 and 7.4%) proportions was −6.1 to 12.6%.

Figures 3 and 4 show the curve fitting for FEV1 and ACT/cACT scores for the entire population and for the two treatment regimen groups and Table 2 the multivariate analysis from randomization to the end of the follow-up.

Median FEV1 ranged from 87 to 88% of predicted values from randomization to the end of the follow-up. In the multivariate regression analysis with time (in months) and treatment regimen as covariate, only the duration of the follow-up explained FEV1 values, i.e., there were no statistically significant differences with respect to this functional parameter between groups (p value = 0.39). Also, they were not statistically different (p = 0.71) also for mean FEV1 values of 87.1% (SD 15%; median of 87%) and 87.2% (SD 17.7%; median of 87%), for intermittent and continuous regimen, respectively.

As for ACT/cACT mean and median scores, they ranged from 21 to 23 points from randomization to the end of the follow-up. Again, after multivariate regression analysis, only the duration of the follow-up determined changes in ACT/cACT (p = 0.38).

Canister weighting revealed that children allocated to the intermittent regimen used from 0.5 to 0.7 puffs/day of beclomethasone, whereas those in the continuous group used from 1.6 to 1.8 puffs/day. The overall amount of beclomethasone administered throughout the study was approximately 210 for the continuous group and 80 for the intermittent group, 60% less. Regarding the intake of albuterol, intermittent arm patients received 0.3–0.4 inhalations per day, against 0.1–0.2 for the continuous one.

As for linear growth, there was no statistically significant difference (p = 0.35) between groups. The intermittent gained 1.6 cm (SD 1.4 cm) whereas the continuous, 1.4 cm (SD 1.6 cm).

Finally, Wilson’s score of allergic rhinitis at the end of the follow-up was 5.3 (SD 3.6) for the intermittent group, and 4.8 (SD 3.4) for the continuous one. There was no statistically significant difference (p = 0.34) in comparing changes, i.e., the treatment of allergic rhinitis led to a comparable degree of control of nasal symptoms in either treatment group.

**Discussion**

In the present study, we did not find any statistically significant difference in clinical and functional characteristics between the two groups. Our results suggest that the intermittent use of beclomethasone is an alternative to reduce future risk of asthma exacerbations, currently recognized as the main patient-related outcome to assess asthma control. Results also suggest that the intermittent regimen can reduce the frequency of exacerbations, even if to a lesser degree than the continuous one. Throughout the follow-up, asthma control, measured through ACT/
cACT and FEV$_1$, was achieved at a satisfactory level in both groups.

Our results are comparable to those observed by Turpeinen et al. [1] and Martinez et al. [2], who carried out studies with similar methodologies, but among affluent populations, and with a longer follow-up. Their main endpoints were lung function, number of exacerbations and growth. They concluded that regular use of inhaled corticosteroids led to better asthma control than the intermittent regimen. In turn, Turpeinen et al. compared the effect of inhaled budesonide given daily (59 patients) or on-demand (58 patients) for mild persistent asthma patients, aged 5–10 years [1].

Martinez et al. [2] assessed the effectiveness of beclomethasone as rescue treatment, through a placebo-controlled study where two out of four groups also received (a) twice daily beclomethasone with beclomethasone plus albuterol as rescue (71 patients), or (b) twice daily beclomethasone with placebo plus albuterol as rescue (72 patients). They concluded that, daily beclomethasone was the most effective treatment to prevent exacerbations, and ICS as rescue medication with albuterol may be an effective step-down strategy for children with well-controlled, mild asthma.

Papi et al. [3] carried out a randomized controlled trial with a similar approach. Rather than inhaled, they used nebulized beclomethasone in 276 pre-school children assigned to three groups. At the end of the 3-month follow-up, the percentage of symptom-free days was higher with regular beclomethasone (69.6%) than with
prn combination (64.9%, p = 0.03). As with the two previously mentioned studies, regular ICS was the most effective treatment for frequent wheezing in preschool children, with on-demand bronchodilator/ICS combination as an alternative.

It is worth noting that in our setting, similar to other low and middle-income countries, shortage and limited access to inhaled corticosteroids brings on the need to look for strategies to optimize the required dose to maintain asthma control and avoid exacerbations.

One of our main findings was that the amount of beclomethasone used by the intermittent group was 60% that of the continuous one. As most asthmatic children requiring continuous use of inhaled corticosteroids suffer from mild persistent asthma, we can estimate that this strategy could reduce by nearly 50% the consumption of beclomethasone used by mild asthmatic patients in a given setting. In other words, as many as double the amount of patients could benefit from the intermittent regimen in low-income settings.

Adherence rate to continuous treatment regimens is a major problem in real life, and it is invariably lower than the prescribed dose because families tend to use these medications intermittently, only to resume therapy when symptoms reappear [13]. Even in more affluent societies, where at least in a part of the population, mean rates can be lower than 60% [14, 15] a rate relatively similar to the consumption of beclomethasone in our intermittent group, patients unwittingly make use of an informal intermittent therapeutic regimen. Therefore, the intermittent strategy is already part of the patients’ or their parents’ habits.

The negative impact of untreated AR on asthma control is well known, since they are pathophysiologically

---

**Table 1 Baseline characteristics by treatment group at randomization**

|                          | Intermittent (n = 94) | Continuous (n = 94) | p value |
|--------------------------|-----------------------|---------------------|---------|
| Age in years, mean (SD)  | 10.6 (2.8)            | 9.9 (2.7)           | 0.09    |
| Sex (boys)               | 55 (58.5)             | 50 (53.2)           | 0.55    |
| Height (cm)              | 145.1 (15.3)          | 142.1 (14.1)        | 0.12    |
| Family monthly income    | 2.4 (1.6)             | 2.3 (1.5)           | 0.55    |
| Mother’s schooling       | 93 (99.0)             | 92 (97.9)           | 0.75    |
| Ethnic group (white)     | 84 (89.3)             | 52 (55.3)           | 0.20    |
| Number of siblings       | 68 (72.3)             | 73 (77.6)           | 0.84    |
| Parental history of AR   | 60 (63.8)             | 64 (68.0)           | 0.87    |
| Parental history of asthma | 54 (57.4)           | 52 (55.3)           | 0.81    |
| Exposure to mould        | 38 (40.4)             | 38 (40.4)           | 0.88    |
| Exposure to house dust mite | 72 (76.6)           | 72 (76.6)           | 0.96    |
| ACT/cACT score, mean (SD)| 21.9 (3.0)            | 22.0 (2.7)          | 0.80    |
| Previous ICS treatment   | 87 (92.5)             | 91 (96.8)           | 0.33    |
| Allergic rhinitis/continuous intranasal budesonide | 36 (38.2) | 29 (30.8) | 0.28 |
| Allergic rhinitis scoring (points)* | 6.6 (3.7) | 6.1 (4.1) | 0.44 |
| Pre-bronchodilator FEV1 (%) mean (SD) | 88.2 (12.1) | 89.8 (12.0) | 0.39 |
| Bronchodilator response (%), mean (SD) | 7.7 (8.5) | 7.2 (7.6) | 0.95 |

Data are proportions (%) or means (SD) unless stated otherwise; one Brazilian minimum wage corresponded approximately to US$ 250.00 during the study period

ACT/cACT asthma control test/childhood-asthma control test, FEV1, forced expiratory volume in 1 s

* Described by Wilson et al. [9]
and clinically related. For this reason, intranasal corticosteroids do improve asthma outcomes in patients suffering from both AR and asthma. To avoid the confounder role of untreated AR among AR patients in the two arms, and differently from the previously mentioned studies [1–3], we included the diagnosis and treatment of all participants with this comorbidity to prevent the negative influence of untreated AR on the pre-defined endpoints in both arms. As expected, the treatment of allergic rhinitis led to a comparable level of control of nasal symptoms in both groups and, at least theoretically, could have contributed to a better asthma control.

Our study have some limitations. The first one is related to the small population; due to financial and operational constraints, we recruited less individuals than the planned sample size. The fact that there was no difference in exacerbation rates could have been caused by lack of power. Secondly, a 16-week follow-up is suboptimal for a study assessing asthma exacerbations as primary outcome. Thus, a longer follow-up would be ideal, as seen in Martinez et al. [2] and Turpeinen et al. [1]. In the Turpeinen study [1], a difference in exacerbation rates was only noted during the second year of the treatment strategy. Likewise, the lack of growth effects and further increases in ACT/cACT and FEV1 values might also be due to lack of power. All in all, the trial is underpowered, and no firm conclusions can be made.

However, as the 95% CI for the difference (3.2%) between the two groups, shows a range that might favor both regimens, we could speculate that adding more patients would not make that much of a difference. It is reasonable to presume that at least one exacerbation may occur within 16 weeks among patients suffering from undertreated/uncontrolled mild persistent asthma. The shape of the longitudinal curves for FEV1 and ACT/cACT showed a homogenous pattern throughout the follow-up, demonstrating a comparable level of clinical and functional control in the two treatment groups.

Conclusion
Our results are in line and confirm those obtained in the three previously mentioned works and, therefore suggest that the intermittent strategy might be used as an alternative regimen for children suffering from mild persistent asthma.

Our study was conducted in a real life primary and secondary public health system facilities network with children from low-income families, which is more likely to increase the clinical applicability of our findings. As pointed out by Martinez et al. [2], this approach might also be an alternative for stepping down beclomethasone after asthma control is achieved among patients suffering from mild persistent asthma especially in poor resource settings.

|                | Intermittent |                | Continuous |                | p value |
|----------------|--------------|----------------|------------|----------------|---------|
|                | Mean   | SD    | Median | Mean   | SD    | Median |          |
| FEV1 (% predicted) |       |       |        |       |       |        |          |
| At randomization | 87.1  | 15.0  | 87.0  | 87.2  | 17.7  | 87.0  | 0.71     |
| At the end of follow up | 91.2  | 23.0  | 88.0  | 82.9  | 22.5  | 87.0  | 0.42     |
| ACT/cACT (points) |       |       |        |       |       |        |          |
| At randomization | 21.9  | 3.0   | 23.0  | 22.0  | 2.7   | 23.0  | 0.80     |
| At the end of follow up | 22.1  | 3.4   | 24.0  | 21.7  | 3.5   | 23.0  | 0.34     |
Finally, clinicians/pediatricians should carefully weigh the potential advantages and disadvantages of each of the two treatment strategies in individualized assessments and possibly in the context of a shared decision-making [17].

Abbreviations
ICS: inhaled corticosteroids; ACT: asthma control test; cACT: childhood asthma control test; FEV1: forced expiratory volume in 1 s; AR: allergic rhinitis; SD: standard deviation.

Authors' contributions
PC and RS designed the study, interpreted the results and drafted the manuscript; AA, GC, LR, MR, NJ, SS, recruited, and followed the subjects, reviewed and approved the final version of the manuscript.

Author details
1 Pediatric Pulmonology Unit, University Hospital, Federal University of Minas Gerais, Avenida Alfredo Balena 190, Room 267, Belo Horizonte 30130-100, Brazil. 2 Municipal Public Health Department, Belo Horizonte, Brazil. 3 Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil.

Acknowledgements
The authors are indebted with Prof. Fernando D Martinez, who discussed with us the original TREXA study protocol, which was duly adapted to the working conditions of our setting, the Belo Horizonte Municipal Health Department that provided the main infrastructural support for the study, and Prof. Alvaro Cruz for reviewing a previous version of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Both the study protocol and written consent were approved by the Ethics in Research Committee of the Municipal Public Health Department, and registered to the official public domain Brazilian Platform for research projects involving human beings (under No. 0048.0.410.000-09A).

Funding
This study was partially supported by a specific Grant (#558332/2009-9) from the Brazilian Council for Research and Technological Development (CNPq) to P. Camargos. P. Camargos is also supported by Minas Gerais State Foundation for Research Development (FAPEMIG, Grant #PPM00665-14). That Brazilian research agency had no influence in the design and conduct of the study; in the collection, management, analysis, and data interpretation; in the writing, review, or approval of the manuscript, and in the decision to submit the paper for publication.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Turpeinen M, Nikander K, Pelkonen AS, Syvanen P, Sorva R, Raitio H, Malmberg P, Juntunen-Backman K, Haathela T. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child. 2008;93:654–9.
2. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, Strunk RC, Szeffler SJ, Zeiger RS, Bacharier LB, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:650–7.
3. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrer R, Rossi GA, Fabbrri LM, on behalf of the BEclomethasone and Salbutamol Treatment (BEST) for Children Study Group. Regular vs pin nebulized treatment in wheeze preschool children. Allergy. 2009;64:1463–71.
4. Nathan RA, Sorkness CA, Kosiinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.
5. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R. Development and cross-sectional validation of the childhood asthma control test. J Allergy Clin Immunol. 2007;119:817–25.
6. Polgar G, Promadhat V. Standard values. Pulmonary function testing in children: techniques and standards. Philadelphia: W.B. Saunders; 1971. p. 87–212.
7. Jentzsich NS, Camargos P, Colosimo E, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy. 2009;64:1458–62.
8. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107–36.
9. Wilson AM, O’Connor SJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 2001;31:1664–24.
10. Dean AG, Sullivan KM, Soe MM. OpenEpi: open source epidemiologic statistics for public health. Version. www.OpenEpi.com. Updated 4 May 2015. Accessed 10 Dec 2016.
11. Liang KY, Zeger SL. Longitudinal data analysis for discrete and continuous outcomes. Biometrika. 1986;73:13–22.
12. Molenberghs G, Verbeke G. Models for discrete longitudinal data. New York: Springer; 2005.
13. Naspietz CK, Cropp GJ. Recommendations for treatment of intermittent mild persistent asthma in children and adolescents. Pediatr Pulmonol. 2009;44:205–8.
14. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Prescription patterns, adherence and characteristics of non-adherence in children with asthma in primary care. Pediatr Allergy Immunol. 2016;27:201–8.
15. Bender BG, Cvietusa PJ, Goodrich GK, Lowe R, Nuanes HA, Rand C, Shettery S, Tacinis C, Wagner N, Wabolts F, et al. Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment: a randomized clinical trial. JAMA Pediatr. 2015;169:317–23.
16. Lasmar LMLB, Camargos PAM, Ondones AR, Gaspar GR, Campos EG, Ribeiro GA. Prevalence of allergic rhinitis and its impact on the use of emergency care services in a group of children and adolescents with moderate to severe persistent asthma. J Pediatr (Rio J). 2007;83:555–61.
17. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. 2013;2:CD009611.

Received: 22 December 2017   Accepted: 17 February 2018
Published online: 05 March 2018